Identification of new SLE-associated genes with a two-step Bayesian study design

Genes and Immunity

Volumn 10, Issue 5, 2009, Pages 446-456

  Armstrong, D L ^a,b   Reiff, A ^a,c   Myones, B L ^d   Quismorio Jr , F P ^a   Klein Gitelman, M ^e   McCurdy, D ^f   Wagner Weiner, L ^g   Silverman, E ^h   Ojwang, J O ⁱ   Kaufman, K M ⁱ   Kelly, J A ⁱ   Merrill, J T ⁱ   Harley, J B ⁱ   Bae, S C ^j   Vyse, T J ^k   Gilkeson, G S ^l   Gaffney, P M ⁱ   Moser, K L ⁱ   Putterman, C ^m   Edberg, J C ⁿ   Brown, E E ⁿ   Ziegler, J ^o   Langefeld, C D ^o   Zidovetzki, R ^b   Jacob, C O ^a   more..

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^j Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^k HAMMERSMITH HOSPITAL   (United Kingdom)

^l MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^m ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁿ The University of Alabama at Birmingham   (United States)

^o WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; GENE PRODUCT; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 16; KILLER CELL LECTIN LIKE RECEPTOR G1; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PROTEIN TYROSINE PHOSPHATASE RECEPTOR TYPE T; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BAYES THEOREM; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; ETHNIC DIFFERENCE; FALSE POSITIVE RESULT; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

AGE OF ONSET; BAYES THEOREM; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 67849088550     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2009.38     Document Type: Article

References (63)

1. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: Cataloging human DNA sequence variation. Science 1997; 278: 1580-1581.
2. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008; 299: 1335-1344.
3. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305: 869-872.
4. Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs HH et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 2007; 39: 513-516.
5. Iles MM. What can genome-wide association studies tell us about the genetics of common disease? PLoS Genet 2008; 4: E33.
6. Hunter DJ, Kraft P. Drinking from the fire hose - statistical issues in genomewide association studies. N Engl J Med 2007; 357: 436-439.
7. Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: Theoretical and practical concerns. Nat Rev Genet 2005; 6: 109-118.
8. Jorgenson E, Witte JS. Coverage and power in genomewide association studies. Am J Hum Genet 2006; 78: 884-888.
9. Cambien F, Tiret L. Genetics of cardiovascular diseases: From single mutations to the whole genome. Circulation 2007; 116: 1714-1724.
10. Armstrong DL, Jacob CO, Zidovetzki R. Function2Gene: A gene selection tool to increase the power of genetic association studies by utilizing public databases and expert knowledge. BMC Bioinformatics 2008; 9: 311-317.
11. Jacob CO, Reiff A, Armstrong DL, Myones BL, Silverman E, Klein-Gitelman M et al. Identification of novel susceptibility genes in childhood-onset Systemic Lupus Erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum 2007; 56: 4164-4173.
12. Cassidy JT. Systemic Lupus Erythemaetosus. In: Cassidy JT, Petty RE (eds). Textbook of Pediatric Rheumatology. Elsevier Saunders: Philadelphia, 1996, pp 329-406.
13. Lehman TJA. Systemic Lupus Erythemaetosus in childhood and adolescence. In: Wallace DJ, Hahn BH (eds). Dubois' Lupus Erythematosus. Lippincott Williams & Wilkins: Philadelphia, 2002, pp 863-884.
14. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
15. Cordell HJ, Clayton DG. Genetic association studies. Lancet 2005; 366: 1121-1131.
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Stat Soc 1995; 85: 289-300.
17. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550-555.
18. Kelly JA, Kelley JM, Kaufman KM, Kilpatrick J, Bruner GR, Merrill JT et al. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun 2008; 9: 187-194.
19. Sigurdsson S, Göring HH, Kristjansdottir G, Milani L, Nordmark G, Sandling JK et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008; 17: 872-881.
20. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 2007; 104: 6758-6763.
21. Siu HO, Yang W, Lau CS, Chan TM, Wong RW, Wong WH et al. Association of a haplotype of IRF5 gene with systemic lupus erythematosus in Chinese. J Rheumatol 2008; 35: 360-362.
22. Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 2005; 77: 685-693.
23. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-678.
24. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B et al A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008; 13: 197-207.
25. Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008; 40: 204-210.
26. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008; 358: 900-909.
27. Kozyrev SV, Abelson AK, Wojcik J, Zaghlool A, Linga Reddy MV, Sanchez E et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 2008; 40: 211-216.
28. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM et al Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 2008; 40: 1059-1061.
29. Altshuler D, Daly M. Guilt beyond a reasonable doubt. Nat Genet 2007; 39: 813-814.
30. Voehringer D, Koschella M, Pircher H. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood 2002; 100: 3698-3702.
31. Erkeller-Yusel F, Hulstaart F, Hannet I, Isenberg D, Lydyard P. Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus. Lupus 1999; 2: 227-231.
32. Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K et al. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 1996; 23: 171-177.
33. Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR. Natural killer cell activity in families of patients with systemic lupus erythematosus: Demonstration of a killing defect in patients. Clin Exp Immunol 2005; 141: 165-173.
34. Stohl W, Elliott JE, Hamilton AS, Deapen DM, Mack TM, Horwitz DA. Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation. Studies in unselected patients and monozygotic disease-discordant twins. Arthritis Rheum 1996; 39: 1840-1851.
35. Beyersdorf N, Ding X, Tietze JK, Hanke T. Characterization of mouse CD4 T cell subsets defined by expression of KLRG1. Eur J Immunol 2007; 37: 3445-3454.
36. Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H. Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol 1998; 37: 1334-1337.
37. Lard LR, Roep BO, Verburgh CA, Zwinderman AH, Huizinga TW. Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 2002; 11: 181-185.
38. Theodore AC, Center DM, Nicoll J, Fine G, Kornfeld H, Cruikshank WW. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J Immunol 1996; 157: 1958-1964.
39. Klimiuk PA, Goronzy JJ, Weyand CM. IL-16 as an antiinflammatory cytokine in rheumatoid synovitis. J Immunol 1999; 162: 4293-4299.
40. McFadden C, Morgan R, Rahangdale S, Green D, Yamasaki H, Center D et al. Preferential migration of T regulatory cells induced by IL-16. J Immunol 2007; 179: 6439-6445.
41. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005; 202: 1575-1585.
42. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
43. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
44. Rhodes B, Vyse TJ. The genetics of SLE: An update in the light of genome-wide association studies. Rheumatol 2008; 47: 1603-1611.
45. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 2003; 63: 6424-6431.
46. Mevorach D. Systemic lupus erythematosus and apoptosis: A question of balance. Clin Rev Allergy Immunol 2003; 25: 49-60.
47. Mehrian R, Quismorio Jr FP, Strassmann G, Stimmler MM, Horwitz DA, Kitridou RC et al. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998; 41: 596-602.
48. Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999; 98: 47-58.
49. Müllauer L, Gruber P, Sebinger D, Buch J, Wohlfart S, Chott A. Mutations in apoptosis genes: A pathogenetic factor for human disease. Mutat Res 2001; 488: 211-231.
50. Staudt LM, Dent AL, Shaffer AL, Yu X. Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL6. Int Rev Immunol 1999; 18 381-403.
51. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL6. Science 1997; 276: 589-592.
52. Ye BH, Cattoretti G, Shen Q, Zhang J, Hawe N, de Waard R et al. The BCL6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet 1997; 16: 161-170.
53. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE et al Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 75: 504-507.
54. Wu H, Cantor RM, Graham DS, Lingren CM, Farwell L, Jager PL et al. Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: Increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. Arthritis Rheum 2005; 52: 2396-2402.
55. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, Nath SK et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases - a meta-analysis. Rheumatology 2007; 46: 49-56.
56. Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci USA 2007; 104: 4060-4064.
57. Julià A, Ballina J, Cañete JD, Balsa A, Tornero-Molina J, Naranjo A et al. Genome-wide association study of rheumatoid arthritis in the Spanish population: KLF12 as a risk locus for rheumatoid arthritis susceptibility. Arthritis Rheum 2008; 58: 2275-2286.
58. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007; 39: 1477-1482.
59. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
60. González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X et al. SNPassoc: An R package to perform whole genome association studies. Bioinformatics 2007; 23: 644-645.
61. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: A toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 2007; 81: 559-575.
62. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21 263-265.
63. Storey JD, Tibshirani R. Statistical significance for genome-wide studies. Proc Natl Acad Sci USA 1995; 100: 9440-9445.